AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video
Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Related Content
The ZEISS Meditec logo in front of a graph showing a line up. Image credit: ©piter2121 – stock.adobe.com

Carl Zeiss Meditec AG announces completed acquisition of Dutch Ophthalmic Research Center

April 4th 2024
Article

Zeiss has secured regulatory approvals to acquire DORC and will shift focus to integration implementation

A detective looks through a magnifying glass at an eyeball. Image created with Canva AI.

Hemorrhagic unilateral retinopathy: No proven aetiology for rare condition

April 2nd 2024
Article

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

A black background with a red line graph going down. Image credit: ©Who is Danny – stock.adobe.com

Increase in the incidence rate of conjunctival melanoma in Australia

March 28th 2024
Article

Investigators analysed the incidence and mortality rates from conjunctival melanoma cases over a 32-year period

Glasses with an overlay of digital data outputs on the surface. Image credit: ©Taiwo – stock.adobe.com

Exonate shares results from Phase Ib/IIa trial of EXN407 eye drops for DR and DME

March 27th 2024
Article

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

A man is on the phone next to the aftermath of a car accident. Image credit: ©Southworks – stock.adobe.com

Assessing long-term impact of ocular injuries after motor vehicle accidents

March 18th 2024
Article

Researchers investigated patients' ability to drive and work following eye injury

An elderly woman clutches her forehead in pain. Image credit: ©Tom Wang – stock.adobe.com

COPHy 2024: Should all elderly patients with acute visual loss go to the emergency department?

March 16th 2024
Article

A case study emphasises the shifting paradigm in clinical best practices

© 2024 MJH Life Sciences

All rights reserved.